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T
hroughout life, stem cells maintain 
themselves by dividing to produce 
one or two daughter stem cells 
with an identical developmental potential. 
Although this self-renewal process is funda-
mental to all types of stem cells, the precise 
mechanism varies between different tissues 
and stages of development. Sean Morrison 
examines the self-renewal of different types 
of stem cells to understand how the process 
declines with age and how it is hijacked by 
cancer cells to drive tumorigenesis.
After a brief stint running a biotech com-
pany in his native Canada, Morrison’s inter-
est in stem cells began as a graduate student 
with Irv Weissman at Stanford University, 
where he developed new techniques to pu-
rify and characterize hematopoietic stem 
cells (1). He then adapted these techniques 
to the nervous system and neural crest stem 
cells as a postdoc with David Anderson at 
Caltech (2). In his own lab at the University 
of Michigan, Morrison goes back and forth 
between the blood and nervous systems, 
identifying new regulators of stem cell self-
renewal and studying how their actions 
change during development and aging (3, 4). 
Morrison’s lab also investigates the self-
renewal of cancer stem cells that are pro-
posed to drive tumor growth (5), while dem-
onstrating that not all cancers follow this 
model of tumorigenesis (6). Morrison has 
challenged other commonly held assump-
tions too, such as the immortal strand 
hypothesis that daughter stem cells always 
inherit older copies of chromosomes (7).
In a recent interview, Morrison discussed 
what his work has taught him about cancer 
and aging, and the importance of explaining 
stem cell research to the general public.
FROM THE ROOTS UP
Where did you grow up and what were 
your earliest experiences of science?
I’m from Nova Scotia in Canada. I did a lot 
of sports and a lot of science fair projects 
growing up. My senior year high school 
project won national awards. It was on 
fungi called Mycorrhizae that colonize 
plant roots and enhance their ability to take 
up nutrients from the soil. The fungus is 
used agriculturally, but it was very expen-
sive and diffi  cult to grow. My lab partner 
and I thought we could grow the fungus 
more effectively using hydroponics and we 
ended up starting a company. The univer-
sity where I did my undergraduate work, 
Dalhousie, gave us lab space, and we’d 
work on it full-time over the summer and 
part-time during the academic year.
I’d run back and forth between the lab 
and classes, and pretty soon I wasn’t going 
to class anymore. I quit school after my 
sophomore year and ran the company full-
time for a few years. We had a successful 
fi  eld trial but the stock market crashed, and 
all the money for biotech dried up, just as I 
was trying to arrange another round of 
fi  nancing. I shut the company down, fi  n-
ished my undergraduate work, and then 
went on to Stanford. So I went to graduate 
school because I failed in biotech!
When did your interest in stem cells 
begin?
After my experience in agricultural biotech, 
I wanted to do medical research because 
everything seemed better funded and more 
competitive. When I joined Irv Weissman’s 
lab, it became clear that stem cell research 
was an exciting area that was going to be 
really big. I developed techniques to purify 
hematopoietic stem cells and distinguish 
them from other blood cell progenitors, 
which made it possible to characterize their 
properties more precisely.
Why did you switch to neural stem cells 
for your postdoc with David Anderson?
I wanted to do something different for my 
postdoc, while carrying over aspects of my 
graduate work. Neural stem cells had 
recently been discovered, but it was early 
days in terms of understanding their biology. 
Everything was based on retrospective anal-
yses of cultured neural cells. If we saw 
multi-  lineage colonies, we’d know that a 
stem cell had been there, but by that point, 
its properties had completely changed, so it 
was impossible to understand what these 
cells were actually doing in vivo. So I took 
the approaches I’d used in my PhD and 
adapted them to the nervous system—iden-
tifying markers for neural crest stem cells, 
purifying them by fl  ow cytometry, and then 
studying the properties of uncultured cells 
that could be transplanted from animal to 
animal. That helped us understand their role 
in the peripheral nervous system.
DIFFERENT STEMS
Did you always plan to go back and 
forth between the blood and nervous 
systems in your own lab?
People were just starting to think that reg-
ulatory mechanisms might be conserved 
between stem cells in different tissues. 
My lab was one of the fi  rst to carefully 
compare different stem cells. Some mech-
anisms are extraordinarily conserved but 
there are others that differ between stem 
cells in different tissues. Identifying both 
types of mechanisms is really important 
to understanding the cells’ biology.
You also compare stem cells across 
time—how does stem cell regulation 
change over an organism’s lifespan?
It’s only in the past fi  ve years or so that 
we’ve begun to understand that stem cell 
self-renewal mechanisms change through-
out life: embryonic stem cells self-renew 
differently from fetal somatic stem cells, 
which, in turn, have different self-renewal 
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mechanisms compared to adult stem cells 
in the same tissue.
The mechanisms continue to change 
as adult cells age. One reason the regen-
erative capacity of tissues declines as you 
get older is that self-renewal programs 
change. Stem cells in many tissues up-
regulate tumor suppressors to shut them-
selves down as they age.
What are the links between stem cell 
self-renewal and cancer?
Cancer is a disease of dysregulated self-
renewal where the cancer cells hijack normal 
stem cell self-renewal programs. When we 
identify new self-renewal mechanisms, they 
invariably turn out to be involved in cancer 
in some way, giving us new insight into 
cancer cell proliferation. I think the age-
dependent changes in stem cell self-renewal 
programs explain the different spectrums of 
mutations you see in childhood versus adult 
cancers. The cancer cells have to hijack a 
different self-renewal program during child-
hood compared to during adulthood, so they 
need different mutations to do it.
Whether tumors are then driven by 
cancer stem cells is controversial. 
Where do you stand on the subject?
We come down in the middle of this debate, 
which is an uncomfortable place to be 
because everyone disagrees with you! We 
think that some cancers really do follow 
the cancer stem cell model in which a 
small sub-population of tumorigenic 
cells proliferate extensively and give rise 
to non-tumorigenic cells that 
form the bulk of the cancer 
and have a limited capacity 
to divide. But there are lots 
of other cancers where we 
think tumorigenic capacity 
is a common attribute of the 
cells. Single melanoma cells 
routinely form tumors when 
we inject them into mice, 
and we’ve not been able to fi  nd  any 
markers that distinguish tumorigenic 
from non-tumorigenic cells. So we have 
to fi  gure out which cancers follow the 
model and which don’t. In some can-
cers, such as brain tumors, it might even 
differ from patient to patient.
It’s critical from a therapeutic point 
of view because if it’s only a rare sub-
population of cancer cells driving tumor 
growth—if it’s a needle in a haystack—
then you’ve got to fi  nd those needles and 
target them directly. But if every cell is 
bad, there’s no point trying to target rare 
cells because that won’t cure the disease.
It seems you like testing key assumptions 
like the cancer stem cell model …
Science involves fi   guring out the truth. 
Sometimes that means discovering new 
mechanisms that nobody’s ever thought 
of before. But sometimes it means testing 
existing mechanisms that haven’t been 
adequately tested.
In the stem cell and cancer fi  elds, there 
are lots of ideas that are intuitively attractive 
to people—and are therefore widely dis-
cussed as if they’re true—but 
which are based on very little 
direct evidence. Those ideas 
really affect the way fi  elds 
develop because they’re the 
prism through which people 
view their own data. So we try 
to test them. Sometimes we 
fi  nd that they’re correct, like 
when we tested the cancer stem 
cell model for acute myeloid leukemias, 
but sometimes we fi  nd those ideas aren’t 
consistent with the data—the ideas might be 
completely wrong or just oversimplifi  ed.
BRANCHING OUT
What is your lab working on now?
We’re doing a lot of experiments related 
to cancer. Although we can’t fi  nd markers 
that distinguish tumorigenic from non-
tumorigenic melanoma cells, we still see 
lots of markers that differ between cells 
from the same patient. Where does this 
heterogeneity come from? We’re trying to 
understand that, and I think it will provide 
new insights into cancer biology.
You’re also involved in public policy. 
Why is that important to you?
If we don’t explain why research is impor-
tant and what it means, we will get bad 
laws for bad reasons. You’d be surprised 
at how few congresspersons really under-
stand the issues they vote on. We have a 
responsibility to explain these things to 
the public so that we have appropriate and 
effective legislation.
When I became the director of the Uni-
versity of Michigan Center for Stem Cell 
Biology, I asked the University to support 
efforts to change state laws that restricted 
embryonic stem cell research. We weren’t 
able to do it through the legislature, so we 
went directly to the people of Michigan 
with a ballot initiative and eventually pre-
vailed. I spent an enormous amount of time 
during that election talking about stem 
cells, and it was an educational experience 
to see how the sausage gets made.
What would you be if you weren’t in 
academia?
I defi  nitely wouldn’t be a politician. I don’t 
like any fi  eld where people just make up 
facts to support their positions. I was shocked 
at the extent to which that happened in the 
campaign to protect stem cell research in the 
Michigan state constitution: opponents were 
unrestrained in inventing things that they 
thought could frighten the public into not 
supporting stem cell research.
If I weren’t in academia, I think I 
would be in biotech. I really enjoyed start-
ing my company as an undergraduate. 
Since I joined the University of Michigan, 
I helped found one company and I consult 
for a few others—I enjoy it very much.
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Neural stem cells reside in the subventricular 
zone, stained here for neurons (red), glia (green), 
and DNA (blue).
“I went to 
graduate 
school 
because I 
failed in 
biotech!”